Corbus Pharma reels in $25M to pay for its PhIIb cystic fibrosis study, shares sink
On Monday Corbus Pharmaceuticals touted a deal with the FDA to limit the primary goal of its Phase IIb trial for lenabasum as a new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
